We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Crosspay is a company that aims to make remittance simpler and cheaper.  The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.

Pitch Rated

55%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £212,581
Personalised Co. is a nutrition company on a mission to help as many people as possible reach their health and wellbeing goals by making supplements accessible and affordable. The company asserts that it provides personalised nutritional products to its consumers. Customers are required to take a quiz on the company's portal, based on which, the company's custom-built algorithm creates nutritionist-approved solutions tailored to the specific needs and goals of each customer. Personalised Co. has delivered 270,000 daily vitamin sachets till date. The company has also raised £192,000 from private investors and its first crowdfunding campaign in 2019. It achieved its milestone month in April 2020 earning £48,000 in revenue and delivering over 1,700 personalised vitamins and protein orders. The company will use the investment to level-up its operations, expand its product line and develop its companion-application.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £401,417
Spotlight Consultations aims to diagnose diseases based on evidence-based questionnaires. The company's Algorithmic Questionnaire (AQ) strives to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. The company estimates that 10% of global health expenditure per annum is spent on diabetes, which is predicted to rise to $825 billion by 2030. Indirect costs from premature death, disability, and diabetes-related health complications add an additional 35% more to this number. Spotlight intends for its AQ to help reduce expenditure and healthcare burden while improving the quality of care and health outcomes. The company will use the investment to support early revenue generation, team expansion and stimulate Research and Development (R&D) tools to cover more diseases like CVD, IBD, chronic pain, and cancers.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £69,682
Moody is a health-tracking application that connects users with customised health, food and fitness advice based on their moods, symptoms and cycles. It endeavours to become a sustainable force for good in women's health. The company argues that women control >80% of household health spend and are 80% more likely than men to use a digital health app. It aims to harness these trends and capitalise on the global remote health care market that is forecast to hit £40 billion by 2025. 'The Moody Month' app featured in publications like Vogue, Grazia and The Guardian. It has witnessed over 136,000 downloads since its Version 1 release in 2019. The app has compiled over 5 million moods to date. The company will use the investment to scale its business globally and reach 1 million subscribers within a four-year time frame.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £142,026
Sendit.Money is a remittance entity. It argues that individuals sending or receiving money in emerging markets can face insecure processes, slow transaction times and incur high costs. Sendit.Money asserts that this is because non-fiat currencies are changed multiple times before they are received. The company aims to change this. Its prototype application for African markets was received amidst positive feedback. It is now building a cost-effective mobile wallet providing a secure and inexpensive way to send and receive money that also allows users to compare transfer fees of different remittance agents in real-time. Sendit.Money was shortlisted as Best Global start-up at the 2020 Wales Startup Awards. The company will build and launch its Most Valuable Product (MVP) in Q3 of 2021. It will also use the funding to begin work with an authorised entity to become an approved representative.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £182,732
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £118,950
Wirex is a UK financial technology company that aims to bring crypto & fiat currencies together on one simple payments portal. The company is building a platform where buying, holding, saving and spending any digital and traditional currency is quick, easy and accessible. The Wirex app supports 12 fiat and 10 crypto currencies, operates in 130 countries, and has more than 3.1 million registered users. Wirex launched the first Visa crypto-enabled payments card in the world. It has a £3 billion cumulative transaction volume and plans to expand to the USA by end-2020. Wirex will use the investment to allow millions of its users to own a share of the brand.

Pitch Rated

54%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £3,703,120
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £270,543
Wombat is an investment platform that encourages millenials in the UK, Europe and beyond to invest in some of the world’s best-known brands for as little as £10. Their mission is to empower the generation of millenials to manage, save and grow money by breaking down barriers to traditional investing. The Wombat app was launched in the summer of 2019, and the company has already acquired more than 5,000 customers. Moreover, the company was nominated as Best Newcomer for the Robo Investing Awards and received positive press coverage. With the proceeds, Wombat is planning to build a strong customer base, fulfil growth strategy with a significant increase in marketing, product development, and to educate customers about investing.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £435,717
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph